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Background: GDF8/myostatin suppresses myogenic differentiation.
Results:The small molecule inhibitors dorsomorphin and LDN-193189 bind to and inhibit the GDF8 receptor ActRII andALK4.
Conclusion: Dorsomorphin and LDN-193189 promote myogenesis in vitro.
Significance: Detailed molecular characterization of small molecule inhibitors targeting the GDF8/myostatin pathway dem-
onstrates their potential and risk when applied to promote muscle development.
GDF8, ormyostatin, is amember of the TGF- superfamily of
secreted polypeptide growth factors. GDF8 is a potent negative
regulator ofmyogenesis both in vivo and in vitro.We found that
GDF8 signaling was inhibited by the small molecule ATP com-
petitive inhibitors dorsomorphin and LDN-193189. These com-
pounds were previously shown to be potent inhibitors of BMP
signaling by binding to the BMP type I receptors ALK1/2/3/6.
We present the crystal structure of the type II receptor ActRIIA
with dorsomorphin and demonstrate that dorsomorphin or
LDN-193189 target GDF8 induced Smad2/3 signaling and
repression of myogenic transcription factors. As a result, both
inhibitors rescued myogenesis in myoblasts treated with GDF8.
As revealed by quantitative live cell microscopy, treatment with
dorsomorphin or LDN-193189 promoted the contractile activ-
ity of myotubular networks in vitro. We therefore suggest these
inhibitors as suitable tools to promote functional myogenesis.
Myostatin, or GDF8 (growth and differentiation factor-8), is
a 25-kDa dimeric polypeptide growth factor, which belongs to
the TGF- superfamily of extracellular ligands. Members of
this family are essential regulators of diverse processes during
embryogenesis as well as in adult homeostasis and regenerative
processes (1). The major role of GDF8 in mammals appears to
be the control of muscle mass. GDF8 knock-out mice feature a
strongly increased muscle mass as a result of both muscle cell
hyperplasia and hypertrophy (2). Inactivating mutations in the
MSTN gene are associated with increased skeletal muscle mass
in cattle, sheep, canines, and humans (3–8).
GDF8 has been described as a potent negative regulator of
myogenesis in vivo and in vitro and therefore has been a
promising therapeutic target in order to promote myogenesis
in muscle-wasting conditions, such as age-related atrophy,
cachexia, or muscular dystrophies (9). There is, however,
increasing evidence that other ligands of the TGF- superfam-
ily, especially BMPs,3 play critical roles in muscle development
and homeostasis (10).
Signaling specificity within the 33-member superfamily of
ligands is achieved by combinatorial interactions of the respec-
tive ligandswith cognate receptor complexes consisting of pairs
of type I and type II receptors on the cell surface (11). Within
this complex, the constitutively active kinase of the type II
receptor activates by transphosphorylation the kinase domain
of the type I receptor (12). Activated type I receptors then inter-
act with and transphosphorylate receptor-activated Smad pro-
teins (R-Smads), which act as transcription factors to regulate
transcription in concert with transcriptional co-activators or
co-repressors (13). In parallel to Smad proteins, TGF- super-
family receptors initiate other signaling pathways that do not
directly involve Smads, such as extracellular signal-regulated
kinase (ERK), p38 mitogen-associated kinase (p38-MAPK), or
Akt pathways, to elicit transcriptional or non-transcriptional
responses (14, 15).
Following secretion and activation, GDF8 binds to its type II
receptor, either activin type II receptor A or B (ActRIIA or
ActRIIB), before a type I receptor, activin-receptor like kinase 4
(ALK4), or -5 (ALK5), is recruited into a heteromeric signaling
complex (16, 17) and in turn phosphorylates primarily the
TGF- Smads, Smad2 andSmad3. Both type I and type II recep-
tors feature an extracellular, N-terminal ligand binding domain
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with a typical three-finger toxin fold (18–21), a single trans-
membrane domain, and a C-terminal serine/threonine kinase
domain (22, 23).
Inhibitors of TGF- superfamily signaling have been devel-
oped mainly by targeting the kinase activity of the type I recep-
tors by ATP-competitive small molecule inhibitors (24, 25). As
a consequence of the structural homology of these receptors,
there is significant cross-reactivity within the family but also
with other kinases, which prompts a more detailed character-
ization of the inhibitors at hand as well an intensified search for
more specific compounds (26).
Although initially identified as Compound C, an inhibitor of
AMP-activated protein kinase, dorsomorphin was later recog-
nized for its potential to induce dorsalization in zebrafish
embryos and to inhibit BMP Smad- and non-Smad signaling by
targeting the BMP type I receptors ALK1, -2, -3, and -6 (27, 28).
The dorsomorphin derivative LDN-193189 shares with dorso-
morphin the central pyrazolo[1,5-a]pyrimidinemoiety and was
reported to target the BMP type I receptors with increased
potency and specificity (29, 30).
Here, we report that dorsomorphin and LDN-193189 activ-
ities, even within the TGF- family, are not restricted to type I
receptors but extend also to the type II receptors ActRIIA and
ActRIIB. We report the co-crystal structure of dorsomorphin
bound to the receptorActRIIA. By targeting the type II and type
I receptors for GDF8, dorsomorphin and LDN-193189 inhib-
ited antimyogenic GDF8 signaling and were efficient promo-
tors of functional myogenesis in vitro in C2C12 cells and pri-
mary human skeletal myoblasts.
EXPERIMENTAL PROCEDURES
Maintenance of Cell Lines—C2C12 cells were obtained from
ATCC andmaintained in Dulbecco’s modified Eagle’s medium
(DMEM; Biochrom) supplemented with 10% FCS, 2 mM L-glu-
tamine, and 100 units/ml penicillin/streptomycin. Human pri-
mary myoblasts were kindly provided by Prof. S. Spuler
(Charité-ECRC, Berlin), which had been obtained from healthy
donors by muscle biopsies with permission of the local ethics
commission (EA 1/203/08) as described previously (31). Cells
were maintained in skeletal muscle cell growth medium (Pro-
moCell) supplemented with SupplementMix C-39365 (Promo-
Cell), 20% FCS, 2 mM L-glutamine, and gentamycin.
Protein Expression—The kinase domains of human ActRIIA
(residues 191–488) and ActRIIB (residues 190–487) were
cloned into the vector pFB-LIC-Bse. Baculoviral expressionwas
performed in Sf9 insect cells at 27 °C, shaking at 110 rpm. Cells
were harvested at 48 h postinfection and resuspended in 50mM
HEPES, pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol,
supplemented with protease inhibitor set V (Calbiochem).
Cells were lysed either using a C5 high pressure homogenizer
(Emulsiflex) or by sonication (Sonics Vibra Cell) on ice. Insol-
uble material was excluded by centrifugation at 21,000 rpm.
Nucleic acids were removed either using a DEAE-cellulose col-
umn or by the addition of 0.15% polyethyleneimine, pH 7.5,
before centrifugation. Proteins were purified using anN-termi-
nal hexahistidine tag by nickel affinity chromatography. The
proteins were eluted using 250 mM imidazole in a buffer com-
prising 50 mM HEPES, 300 mM NaCl, 0.5 mM tris-(2-carboxy-
ethyl)phosphine. The eluted protein was cleaved with tobacco
etch virus protease and further purified by size exclusion chro-
matography using a S200 HiLoad 16/60 Superdex column. A
final cleanup step was performed if necessary using reverse
purification on a Ni-Sepharose column. The buffer was
adjusted to 50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM
DTT, 50 mM L-arginine, and 50 mM L-glutamate for crystal-
lization trials.
Crystallization, Data Collection, and Structure Determi-
nation—Crystallization was performed using the sitting drop
vapor diffusionmethod at 20 °C.ActRIIAprotein buffered in 50
mM Hepes, pH 7.5, 300 mM NaCl, and 0.5 mM tris-(2-carboxy-
ethyl)phosphinewas concentrated to 20mg/ml andmixedwith
1 mM dorsomorphin. Viable crystals were obtained in a 150-nl
drop mixing the protein and the reservoir solution containing
28% PEG3350, 0.2 M lithium sulfate, 10% ethylene glycol, and
0.1 M Tris-HCl, pH 8.8, at a 1:1 volume ratio. Crystals were
cryoprotected with the mother liquor supplemented with 20%
ethylene glycol before vitrification in liquid nitrogen. Diffrac-
tion data collected at the Diamond Light Source beamline I03
were processed and scaled with MOSFLM (32) and Scala from
the CCP4 suite (33), respectively. The structure determination
was achieved by molecular replacement using the program
Phaser (34) and the coordinates of ActRIIB (23) as a search
model. Subsequent manual model building alternated with
structure refinement was performed inCOOT (35) and Refmac
(36), respectively. A TLS model calculated from the TLSMD
server (37) was used in the late refinement step. The finalmodel
was verified for its geometric correctness with MOLPROBITY
(38).
Isothermal Titration Calorimetry—Isothermal titration calo-
rimetry experiments were performed at 15 °C using a VP-ITC
instrument (Microcal/GE Healthcare). Proteins and ligands
were buffered in 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM
tris-(2-carboxyethyl)phosphine, 2% DMSO. Heats of dilution
were determined in a separate experiment and subtracted from
the final data. The resulting data were fitted using the non-
linear least squares curve fitting algorithm implemented in the
Origin software provided with the instrument. Reported errors
correspond to those derived from the fitting procedure.
Thermal Shift Assay—Thermal melting experiments were
performed using a real-time PCR machine, Mx3005p (Strat-
agene), with a protein concentration of 2Mand 12.5M inhib-
itor as described previously (39, 40). A kinase-directed com-
pound set was assembled from commercial suppliers, including
Biofocus (DPI) and Calbiochem. Screening was performed
using a construct of the human ActRIIA protein comprising
residues 186–494.
Phosphoprotein Assays and Western Blot Analysis for Myo-
genic Markers—Primary human myoblasts before or during
differentiation or C2C12 myoblasts in 12-well plates were
starved for 3 h in DMEM, 0.2% FCS, followed by pretreatment
with the respective inhibitors, dorsomorphin (Calbiochem),
LDN-193189 (Sigma-Aldrich), SB-431542 (Sigma-Aldrich),
or DMSOas a vehicle control. Cells were stimulated or notwith
ligands, rhBMP2 (kind gift by Prof. W. Sebald, Würzburg),
rhGDF8 (R&D Systems), recombinant human TGF-1 (Tebu-
Bio), or concentration-matched vehicle control. Cells were
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lysed directly in SDS sample buffer, and proteins were detected
by SDS-PAGE and Western blotting using antibodies for
skeletal type II myosin heavy chain (Sigma-Aldrich), phos-
pho-Smad2 (Zymed Laboratories), phospho-Smad1/5 (Cell
Signaling), phospho-p38 (Promega), GAPDH (Cell Signaling),
or -tubulin (Sigma-Aldrich) in combination with species-spe-
cific HRP-conjugated secondary antibodies (Dianova). Che-
moluminescence (Femto-Glo ECL, P.J.K) was recorded using
the ChemiSmart5000 digital imaging system (Vilber-Lourmat).
Signal intensities were quantified densitometrically on 16-bit
raw images using Bio1D software (Vilber-Lourmat).
For the detection of myogenic marker proteins after short
term differentiation, confluent C2C12 cells were switched to
differentiationmedium (DMEMcontaining 2%horse serum) in
the presence or absence of GDF8 and inhibitors as indicated.
After direct cell lysis in SDS sample buffer, lysates were ana-
lyzed by SDS-PAGE and immunoblotting for the myogenic
transcription factors MyoD (Santa Cruz Biotechnology) and
myogenin (Santa Cruz Biotechnology). GAPDH (Cell Signal-
ing) served as a loading control.
Luciferase Reporter Gene Assays—For Dual-Luciferase assays,
C2C12 cells were transfected in 96-well plates with inducible
BRE-luciferase or (CAGA)12-luciferase reporter gene con-
structs together with constitutively expressedRenilla luciferase
(pRLTK-luc) (41, 42). After 16 h, cells were starved for 2 h and
stimulated for 6 h with ligand in the presence or absence of
kinase inhibitors as described at the indicated concentrations.
Luciferase activity was quantified using the Dual-Luciferase
reporter gene assay in aMithras LB940multimode plate reader
(Berthold Technologies).
For Myg-luciferase assays, C2C12 cells were transfected in
96-well plates with the myogenin-luciferase construct (43). At
confluence, cells were pretreated with inhibitors for 30 min
before stimulation with ligand as indicated or DMSO vehicle
control in differentiation medium (DMEM plus 2% horse
serum). After 3 days of differentiation, cells were lysed, and
firefly luciferase activity was measured as described.
Monitoring and Quantification of Myogenic Differentiation
by Immunofluorescence Microscopy—To monitor the initial
phase of myogenic differentiation in vitro, primary human
TABLE 1
Inhibitor screening for ActRIIA
Rank Tm shift KD Inhibitor Supplier Supplier ID
° C
1 10.67 14 nM LDN-193189 Paul Yu, Harvard LDN-193189
2 9.75 K02288 BioFocus 382_0087_0284
3 9.18 Cdk1/2 inhibitor III Calbiochem (EMD) 217714
4 9.15 Alsterpaullone, 2-cyanoethyl Calbiochem (EMD) 126871
5 8.45 58 nM Dorsomorphin Tocris 3093
6 8.34 GSK inhibitor XII Calbiochem (EMD) 361554
7 8.04 NSC-664704 Calbiochem (EMD) 422000
8 7.88 K252a Calbiochem (EMD) 420298
9 6.48 Indirubin E804 Calbiochem (EMD) 402081
10 6.2 Cdc7/CDK9 inhibitor Calbiochem (EMD) 217707
11 5.93 Quercetin Calbiochem (EMD) 551600
12 5.72 Aloisine A Calbiochem (EMD) 128125
13 5.6 NSC-664704 Calbiochem (EMD) 422000
14 5.5 Apigenin Calbiochem (EMD) 178278
15 5.03 Indirubin-3 monoxime Calbiochem (EMD) 402085
16 4.98 JNK inhibitor V Calbiochem (EMD) 420129
17 4.68 IKK inhibitor VII Calbiochem (EMD) 401486
18 4.19 1-Na-PP1 Calbiochem (EMD) 529579
19 4.15 TGF RI Inhibitor IV Calbiochem (EMD) 616454
20 4.12 Aurora/Cdk inhibitor Calbiochem (EMD) 189406
TABLE 2
Inhibitor screening for ActRIIB
Rank Tm shift KD Inhibitor Supplier Supplier ID
°C
1 15.52 GSK inhibitor XII Calbiochem (EMD) 361554
2 14.6 NDa LDN-193189 Paul Yu (Harvard) LDN-193189
3 12.22 K02288 BioFocus 382_0087_0284
4 11.17 NSC-664704 Calbiochem (EMD) 422000
5 10.87 TGF RI Inhibitor IV Calbiochem (EMD) 616454
6 10.68 Alsterpaullone, 2-cyanoethyl Calbiochem (EMD) 126871
7 10.18 LY 364947 Calbiochem (EMD) 2718
8 9.74 Quercetin Calbiochem (EMD) 551600
9 8.91 K252a Calbiochem (EMD) 420298
10 8.57 Cdc7/CDK9 inhibitor Calbiochem (EMD) 217707
11 8.21 Apigenin Calbiochem (EMD) 178278
12 8.14 WHI-P180 Calbiochem (EMD) 681500
13 7.99 30 nM Dorsomorphin Tocris 3093
14 6.6 Indirubin E804 Calbiochem (EMD) 402081
15 6.28 Aloisine A Calbiochem (EMD) 128125
16 6.17 TGF RI Inhibitor IV Calbiochem (EMD) 616454
17 6.14 JNK inhibitor II Calbiochem (EMD) 420119
18 5.62 1-Na-PP1 Calbiochem (EMD) 529579
19 5.46 Dasatinib Sequoia 863127-77-9
20 5.32 TPCA-1 Tocris TPCA-1
a Not determined.
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myoblasts or C2C12 cells were grown to confluence in 24- or
12-well plates, respectively. Medium was replaced by differen-
tiation medium (DMEM containing 2% horse serum) with or
without inhibitors, human recombinant Noggin (kind gift by
Dr. A. Economides, Regeneron Pharma, Tarrytown, NY), or
DMSO as well as GDF8 at the indicated concentrations. After 3
days of differentiation, cells were paraformaldehyde-fixed, per-
meabilized by Triton X-100, and immunostained using anti-
bodies for skeletal type II myosin heavy chain (Sigma-Aldrich).
Nuclei were stained with DAPI. Myogenic differentiation was
documented using a Zeiss Axiovert 200M epifluorescence
microscope and Axiovision (Carl Zeiss) software.
For extended periods of myogenic differentiation, primary
human myoblasts or C2C12 cells were grown to confluence in
Matrigel-coated or uncoated 24-well plates, respectively, and
allowed to undergo myogenic differentiation for 4 days. From
day 4 of differentiation, cells were treated with dorsomorphin
or DMSO as vehicle control in fresh differentiationmedium for
another 2 days. After 6 days, myogenic differentiation was visu-
alized as described above.
For high resolution immunofluorescencemicroscopy of long
term differentiation, C2C12 cells were grown to confluence on
Matrigel-coated 8-well Permanox multichamber slides before
the medium was replaced by differentiation medium. Cells
were treated with dorsomorphin in fresh differentiation
mediumat day 4 of differentiation and again at day 5 before they
were processed for immunofluorescence at day 6 as described.
Digital images of myosin heavy chain (MHC) and DAPI
channels were quantified using a macro that provided batch
operability for the ImageJ distribution Fiji (44). Using an auto-
mated procedure for homogeneous data sets, MHC-positive
areas were quantified as fractions of the total image area. In
addition, using MHC-positive areas to define region of interest
masks, the accumulated DAPI signals within these regions of
interest were used to quantify the fractions of nuclear staining
in MHC-positive areas.
Live Cell Monitoring and Quantification of Myotube Twitch-
ing Activity—C2C12 cells were grown to confluence in 6-well
plates before medium was replaced by differentiation medium.
At day 4 of differentiation, the differentiation medium was
replaced by differentiation medium containing dorsomorphin,
LDN-193189, or DMSO as vehicle control. The contractile
twitching of myotubes was recorded at day 6 by live cell differ-
ential interference contrast (DIC) microscopy on a Zeiss Axio-
vert 200M microscope using Axiovision software (Carl Zeiss).
The contractile activity was quantified by analyzing movies
of time lapse image series (3.3 frames/s, 86 frames). All image
processing steps were performed with the Fiji ImageJ distribu-
tion (44). First, we checked all movies for proper image align-
ment (registration) and unimpaired illumination. Next, we
applied a Gaussian smoothing of two pixels to reduce image
noise. Then active image areas were visualized by the Image
CorrelationJ plugin evaluating the local correlation in pre-
defined regions of two successive frames (45). In the resulting
correlation maps, we determined and removed inactive pixels
by thresholding each image. The activity at a specific time point
is given by the sum of active pixels related to the total pixel
number in each frame.
RESULTS
Dorsomorphin and LDN-193189 Bind ActRIIA Similarly to
ALK2—In vitro kinase assays have shown that LDN-193189
potently inhibits the kinase activity of ALK4 and ActRIIA with
IC50 values of 101 and 210 nM, respectively (26). Furthermore,
KINOMEscan (DiscoveRx) profiling of LDN-193189 against 451
kinases has identified ActRIIA and ActRIIB as the second and
ninth strongest binders after ALK2, with 96 and 88% binding at
100 nM inhibitor concentration, respectively (46). To confirm the
significance of these interactions, we screened the ActRII kinases
against a large panel of commercially available kinase inhibitors
using a thermal shift assay. The top 20 hits for each kinase are
reported inTables 1 and 2. Significantly, LDN-193189was ranked
as the top inhibitor hit for ActRIIA and second for ActRIIB,
whereas dorsomorphin was also among the top ranked inhibitors
for both kinases. Binding measurements determined by isother-
mal titration calorimetry (ITC) showed that both compounds had
KD values in the range 14–58 nM (Tables 1 and 2).
Crystallization trials were performed with both dorsomor-
phin and LDN-193189 to explore the mechanism of inhibition
of the type II receptors. Crystals were obtained of ActRIIA with
dorsomorphin, fromwhich the complex structure was deter-
mined to 2.0 Å resolution with two protein molecules in the
asymmetric unit and clear electron density for the bound
ligand (see Table 3 for data collection and refinement statis-
tics). The structure represents the first reported of the
ActRIIA kinase domain (Fig. 1A) and reveals an active con-
formation with high similarity to that of ActRIIB (root mean
square deviation of 0.9 Å over 289 C atoms). Differences are
restricted to the activation loop, which probably reflects the
inherent flexibility of this region.
The high affinity binding of dorsomorphin (Fig. 1,B andC) is
characterized by a single hydrogen bond to the hinge residue
His-270 as well as a hydrogen bond from the pendant pyridine
TABLE 3
Data collection and refinement statistics
ActRIIA-dorsomorphin
Protein Data Bank accession code 3Q4T
Data collection
Beamline Diamond, beamline I03
Wavelength (Å) 0.9763
Resolution (Å) 48.60-1.96 (2.07-1.96)a
Space group P 65 2 2
Cell dimensions a b 110.1, c 206.9 Å
  90.0°,  120.0°
No. of unique reflections 53,883 (7,727)
Completeness (%) 99.9 (100.0)
I/I 11.2 (2.3)
Rmerge 0.112 (0.783)
Redundancy 7.0 (7.2)
Refinement
Ligands Dorsomorphin
No. of atoms in refinement (P/L/O)b 4,899/60/613
Rfact (%) 16.9
Rfree (%) 22.3
Bf (P/L/O)b (Å2) 30/56/40
Root mean square deviation, bond (Å) 0.016
Root mean square deviation, angle (degrees) 1.5
Molprobity
Ramachandran favored (%) 97.1
Ramachandran allowed (%) 100
a Values in parentheses show the statistics for the highest resolution shells.
b P/L/O, protein/ligand molecules presented in the active sites/other (water and
solvent molecules).
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to the catalytic 3-strand residue Lys-219, which is also posi-
tioned to form the typical salt bridge with the C residue Glu-
232. Overall, the binding mode is highly conserved with that
observed in ALK2 (Fig. 1D). However, in the inactive ALK2
structure, the salt bridge between the catalytic3 lysine andC
glutamate is broken, and the pyridine nitrogen of dorsomor-
phin instead forms a water-mediated hydrogen bond to Glu-
248 (C) (Fig. 1D). The binding interactions of ActRIIB are
predicted to be similar to ActRIIA, with which the ATP pocket
residues are strictly conserved (Fig. 1E). Modeling of LDN-
193189 is facilitated by the previous co-structure with ALK2
(26). Its interactions are also conserved with dorsomorphin,
except for the larger 4-quinoline group, which provides addi-
tional hydrophobic interaction (Fig. 1E).
Dorsomorphin and LDN-193189 Inhibit GDF8-induced Sig-
naling Pathways in Primary Human Myoblasts and in C2C12
Myoblast Precursors—Based on these results, we evaluated the
potential for dorsomorphin and LDN-193189 to inhibit GDF8-
induced Smad2/3 phosphorylation in different cell types of the
myogenic lineage. Primary human myoblasts were differenti-
ated in vitro for 6 days. Pretreatment with 5 M dorsomorphin
or 0.5 M LDN-193189 interfered with GDF8-induced Smad2/3
phosphorylation (Fig. 2A). A similar effect of dorsomorphin
and LDN-193189 treatment was observed in undifferentiated
primary humanmyoblasts as well as in themousemyoblast cell
line C2C12 (Fig. 2, B and C). Repression by LDN-193189 was
significantly stronger than by dorsomorphin. In addition, treat-
ment with LDN-193189 also affected GDF8-induced non-
Smad signaling, as indicated by reduced p38 MAPK phos-
phorylation. The relative efficiency of inhibitor treatment
was confirmed in more detail in C2C12 cells. Phosphoryla-
tion of Smad2/3 was significantly reduced at a concentration
of 0.5 M LDN-193189, whereas 5 M dorsomorphin was
required to achieve the same effect (Fig. 2D). The finding
that myostatin/GDF8 signaling could be blocked by these
putative type I BMP receptor kinase inhibitors in cells of the
FIGURE 1. Inhibitor binding to ActRII. A, overview of the ActRIIA crystal structure showing dorsomorphin bound in the ATP pocket. B, interactions of
dorsomorphinwithActRIIA. The inhibitor formsdirect hydrogenbondswith the kinasedomainhinge residueHis-270 aswell aswith the catalytic lysine residue
Lys-219,which in turn forms a salt bridgewith the catalytic glutamateGlu-232.C, bindingmeasurements using ITC show that dorsomorphinbindsActRIIAwith
a KD value of 58 nM.D, superposition of the ActRIIA and ALK2 (53) structures reveals a similar inhibitor binding pocket. For clarity, only dorsomorphin from the
ActRIIA structure is shown. Residue numbers are given for ActRIIA, and any substitutions in ALK2 are shown in parentheses. In ActRIIA, the catalytic lysine
(Lys-219) forms a bridging hydrogen bonding interaction between dorsomorphin and the catalytic glutamate (Glu-232), whereas in ALK2, the catalytic lysine
is displaced, and this interaction is instead mediated by a water molecule. E, superposition of the ActRIIA and ActRIIB structures (23) reveals the strict
conservation of the residues lining the respective ATP binding pockets. The inhibitor LDN-193189 (magenta stick representation) was modeled based on the
bound LDN-193189 in ALK2 (26) and the bound dorsomorphin (gray stick representation) in this ActRIIA structure. Residue numbers are given for ActRIIA, and
any substitutions in ActRIIB are shown in parentheses.
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myogenic lineage led us to investigate the mechanisms of
action of dorsomorphin and LDN-193189 inhibition in more
detail.
Receptor Kinase Inhibitors Exhibit Distinct Specificities for
Smad Signaling Induced by TGF- Family Ligands—We next
compared the effects of dorsomorphin, LDN-193189, and the
ALK4/5/7 inhibitor SB-431542 on the transcriptional activity
ofGDF8 orTGF--induced (CAGA)12-luciferase reporter gene
activity and on BMP2-stimulated activation of the BRE-lu-
ciferase reporter, in C2C12 cells. The (CAGA)12-luciferase
reporter is activated by the TGF- R-Smad, Smad3, together
with Smad4, whereas BRE is activated by the BMP R-Smads
Smad1/5/8 together with Smad4 (41, 42). We found that 5
M dorsomorphin and 0.5 M LDN-193189 were sufficient
to repress GDF8-induced (CAGA)12 -luciferase activity (Fig.
3A) by more than 50%. The effect of dorsomorphin was com-
parable with that of SB-431542, whereas LDN-193189 was
even more potent. As expected, the BMP-induced activation
of BRE was also efficiently inhibited by 5 M dorsomorphin
and 0.5 M LDN-193189, whereas SB-431542 had no effect
(Fig. 3B). By contrast, dorsomorphin and LDN-193189 were
less efficient in repressing TGF--induced (CAGA)12 activa-
tion (Fig. 3C). Even at 5 M, dorsomorphin or LDN-193189
did not abolish TGF- induced (CAGA)12-luciferase activa-
tion, unlike SB-431542.
The specific effects on ligand-induced Smad transcriptional
activity were confirmed by monitoring Smad phosphorylation.
Pretreatment with dorsomorphin or LDN-193189 led to
reduced levels of phosphorylated Smad2/3 following GDF8
stimulation (Fig. 4A), which were comparable with their effects
on BMP2-induced phosphorylation of Smad1/5 (Fig. 4B),
whereas therewas no effect onTGF- induced Smad2/3 signals
(Fig. 4A). Taken together, in addition to their known effect on
BMP2-induced transcription, we could confirm that dorso-
morphin and LDN-193189 efficiently inhibited Smad signaling
initiated by GDF8 stimulation.
FIGURE 2.Dorsomorphin and LDN-193189 inhibit GDF8-induced signaling pathways in undifferentiated and in differentiated primary humanmyo-
blasts and in C2C12 premyoblasts. A, primary human myoblasts were allowed to differentiate to myotubes for 6 days, as indicated by expression of MHC.
Cells were then serum-starved and pretreated for 30 min with 5 M dorsomorphin or 0.5 M LDN-193189, before they were stimulated for 45 min with 8 nM
GDF8. GDF8-induced phosphorylation of Smad2/3 and p38 was detected by immunoblotting and quantified densitometrically. B, undifferentiated primary
human myoblasts were serum-starved, preincubated for 30 min with 5 M dorsomorphin or 0.5 M LDN-193189, and stimulated for 45 min with 8 nM
GDF8. The absence of MHC expression indicates the undifferentiated status. GDF8-induced phosphorylation of Smad2/3 and p38 was detected by
immunoblotting and quantified densitometrically. C, serum-starved C2C12 premyoblasts were pretreated for 30min with 5M dorsomorphin or 0.5M
LDN-193189 before stimulation for 45 min with GDF8. GDF8-induced phosphorylation of Smad2/3 and p38 was detected by immunoblotting and
quantified densitometrically. D, serum-starved C2C12 premyoblast cells were pretreated for 30 min with increasing concentrations of dorsomorphin or
LDN-193189 before stimulation for 45 min with 4 nM GDF8. GDF8-induced phosphorylation of Smad2/3 was detected by immunoblotting and quanti-
fied densitometrically.
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Dorsomorphin or LDN-193189 Promotes Myogenesis in
Vitro—To investigate whether inhibition of GDF8-induced
Smad2/3 phosphorylation and transcriptional activity was
functionally relevant, myogenic differentiation of C2C12 cells
wasmonitored in vitro. As expected, treatmentwithGDF8 sup-
pressed the up-regulation of myogenic markers MyoD and
myogenin (Fig. 5A). In the presence of dorsomorphin or LDN-
193189, however, this suppressive effect of GDF8 was abol-
ished, and myogenic differentiation was restored.
Besides GDF8, myogenic differentiation of C2C12 cells is
known to be attenuated by BMP2 as well as by TGF- (47–49).
Using a luciferase reporter gene under the control of the myo-
genin promoter (Myg-luc), the expected antimyogenic effects
of these growth factors were observed (Fig. 5B). Conversely,
inhibition of BMP-2 or TGF-1 signaling by dorsomorphin,
LDN-193189, or SB-431542, respectively, promotedMyg-lucif-
erase activity. On the other hand, in cells that were stimulated
with GDF8, Myg-luciferase activity was also increased by dor-
somorphin or LDN-193189 treatment, although inhibiting
ALK5 by SB-431542 was slightly more effective to promote
Myg-luciferase activity.
To further explore the potential of dorsomorphin and LDN-
193189 to inhibit the antimyogenic effects of GDF8, the initial
phase ofmyogenic differentiation of C2C12 cells was visualized
by immunofluorescence microscopy, in which the expression
of MHC was visualized and quantified. Images were quantified
using ImageJ in a standardized macro-operated procedure
regarding the numbers of nuclei that were in MHC-positive
areas as well as the totalMHC-positive area. Although the pres-
ence of GDF8 stimulation strongly suppressed the formation of
MHC-positive myotubes after 3 days of differentiation, con-
comitant treatment with dorsomorphin or LDN-193189 coun-
teracted GDF8, resulting in increased MHC expression (Fig.
5C). In cells thatwere not stimulatedwith exogenousGDF8, the
promyogenic effect of dorsomorphin or LDN-193189was com-
parable with that of the BMP antagonist noggin, which was
used to scavenge autocrine BMPs (Fig. 5D). To investigate
whether dorsomorphin and LDN-193189 were also capable of
counteracting GDF8 signaling in cells committed to the myo-
genic lineage, primary human myoblasts were treated with
GDF8 in the presence or absence of dorsomorphin or LDN-
193189. Similar to C2C12 cells, the formation of myotubes as
well asMHCexpressionwere attenuated byGDF8 and could be
restored by either dorsomorphin or LDN-193189 (Fig. 5E).
The positive effects of dorsomorphin and LDN-193189 on
myotube formation raised the question whether a similar pro-
myogenic effect was true for later stages of myogenic differen-
tiation. To this end, C2C12 cells or primary human myoblasts
were allowed to differentiate for 4 days before they were treated
with dorsomorphin for the following 2 days. In addition, the
effects of an extracellular BMP antagonist, noggin, were evalu-
ated in C2C12 cells. At day 6 of differentiation, the formation of
a myotubular network was visualized by MHC immunocyto-
chemistry. In both cell types, dorsomorphin treatment resulted
in increasednumbers of nuclei thatwere inMHC-positive areas
and of the total MHC-positive area (Fig. 6,A and B). Of note, at
this stage, noggin alone did not promote myogenesis; nor did
noggin further enhance myogenesis in dorsomorphin-treated
cells. The myotubular networks that formed in the presence of
dorsomorphin revealed the typical morphology and internal
organization of contractile myotubes, as represented by inter-
mittent MHC staining of A-bands (Fig. 6C) (50).
To confirm the potential of dorsomorphin and LDN-193189
to promote functional myogenesis in vitro, the contractility of
myotubular networks formed by C2C12 cells after 6 days of
differentiation was recorded by live cell DICmicroscopy. Based
on the resulting time lapsemovies, areas of twitchingmyotubes
FIGURE 3.Dorsomorphin and LDN-193189 efficiently inhibit GDF8 induced
Smad3/4 reporter gene activity. Undifferentiated C2C12 cells were trans-
fected with Smad3/4-responsive (CAGA)12-luciferase or Smad1/5-responsive
BRE-luciferase reporter constructs together with constitutively expressed
Renilla luciferase overnight. Cells were serum-starved and stimulated for 6 h
with 20 nM GDF8, 100 pM TGF-, or 10 nM BMP2, together with the receptor
kinase inhibitors dorsomorphin, LDN-193189, and SB-431542, as indicated.
Luciferase activities are presented as relative luciferase units (RLU; firefly lucif-
erase activity normalized to Renilla activity). Bars, mean S.D. (error bars) of
triplicates. A, dorsomorphin and LDN-193189 repressed GDF8-induced
(CAGA)12-luciferase activity from 0.5 and 0.05 M, respectively. B, BMP2-in-
duced BRE-luciferase activity was efficiently repressed by 0.5 M dorsomor-
phin or 0.05 M LDN-193189. C, TGF--induced (CAGA)12-luciferase activity
was repressed by 5 M dorsomorphin or 0.5 M LDN-193189.
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were visualized, and the twitching activity was quantified (Fig.
7, A and B). In line with our findings that dorsomorphin pro-
moted terminal differentiation and the formation of myotubu-
lar networks, quantitative analysis revealed an increased con-
tractile activity in response to treatment with dorsomorphin or
LDN from day 4 to 6 (Fig. 7B).
Taken together, our data demonstrate that both dorsomorphin
and LDN-193189 act as potent promoters of myogenic differenti-
ation. Of note, depending on the time of administration, dorso-
morphin and LDN-193189were capable of promoting both initial
and terminal phases of muscle cell differentiation.
DISCUSSION
ANewLight onDorsomorphin and LDN-193189 Specificity—
The search for specific inhibitors of TGF- superfamily path-
ways in the past decade was primarily focused on targeting the
type I receptors (51). This is reasonable with respect to their
position in the pathway directly upstream of Smad activation
and of non-Smad pathways (27, 28, 30). Moreover, to date, all
known activating mutations in receptors of the TGF- super-
family map to type I receptors, which makes their specific inhi-
bition desirable from a therapeutic point of view (52, 53).
Studies to determine the specificity of small molecule inhib-
itors (54, 55) of TGF- superfamily receptors have been per-
formed with immunoprecipitated or recombinant proteins
either by using in vitro kinase assays or by in vitro binding
assays, such as ITC or thermal shift determination, as well as by
crystal structures. In complementary cell-based assays, either
single constitutively active ALK receptors or limited sets of
TGF- or BMP isoforms, in most cases TGF-1 or BMP-2, -4,
-6, or -7, were used to induce Smad2/3 or Smad1/5/8 phosphor-
ylation, respectively, or Smad-dependent reporter gene activa-
tion (26, 27, 30, 46).
Here we demonstrate that dorsomorphin and LDN-193189
can also inhibit GDF8 signaling. Both inhibitors could interfere
withGDF8-induced phosphorylation and transcriptional activ-
ity of Smad2/3 in GDF8-responsive cell types of the myogenic
lineage and at different stages of myogenic commitment.
The concentrations yielding significant, although incomplete,
repressionwere 5Mdorsomorphin or 0.5MLDN-193189. At
the same concentrations, inhibition of BMP2-induced Smad1/
5 signaling was nearly complete, whereas TGF--induced
Smad2/3 signaling was only slightly affected.
These effects are consistentwith the reported inhibitor activ-
ities using in vitro kinase assays. For example, LDN-193189 is
notably more active against the GDF8 receptors ALK4 (IC50
101 nM) and ActRIIA (IC50  210 nM) compared with ALK5
(IC50 350 nM), although all of these kinases are inhibited less
efficiently than theBMP-specificALKs (IC50 values in the range
FIGURE 4. Ligand-specific effects of kinase inhibitors on Smad2/3 and Smad1/5 phosphorylation. Serum-starved C2C12 cells were pretreated for 30min
with 0.5 M (left panels) or 5 M (right panels) dorsomorphin, LDN-193189, or SB-431542, before stimulation for 45 min with 5 nM BMP2, 8 nM GDF8, or 100 pM
TGF-1. Phosphorylated Smad2/3 (A) or Smad1/5 (B) was detected by immunoblotting and quantified densitometrically.
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0.8–16.7 nM) (26). The strong binding of dorsomorphin to
ActRIIA is additionally demonstrated by our co-crystal struc-
ture with the ActRIIA kinase domain as well as by our Tm shift
and ITC assay data using both ActRIIA and ActRIIB.
Interestingly, the type II TGF- receptor TRII is inhibited
by LDN-193189 (IC50  140 nM) in the same concentration
range as ActRIIA (56). Thus, the cellular efficacy of this inhib-
itor against TGF- signaling is most likely limited by its low
potency against ALK5. Currently, there are no available struc-
turalmodels for the TRII kinase domain, but its ATP pocket is
expected to share considerable structural and sequence conser-
vation with both ALK2 and ActRIIA. In particular, the hinge
region of TRII shares a threonine side chain as its gatekeeper
residue, a site most frequently associated with inhibitor selec-
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tivity in active kinases (57). In contrast, the type II BMP recep-
tor BMPR2 contains a larger methionine side chain as its gate-
keeper receptor. This side chain is predicted to sterically
interfere with LDN-193189 binding, and indeed a lack of bind-
ing has been reported (46).
Thus, we suggest that the pronounced effect of dorsomor-
phin or LDN-193189 on GDF8-induced signaling may result
from the functional synergism of inhibiting both theGDF8 type
II (ActRIIA and -B) and type I (Alk4 and Alk5) receptors. Our
conclusion raises the possibility of achieving functional speci-
ficity with inhibitory compounds that target more than one
signaling component with intermediate efficiency rather than
being highly specific and efficient for a single component. This
concept may inspire the search for strategies to interfere with
specific functions of pleiotropic signaling pathways.
Over the years, evidence has accumulated that the separation
between TGF--induced Smad2/3, on one hand, and BMP-in-
duced Smad1/5/8, on the other hand,may be less stringent than
previously thought (54, 58, 59). In these studies, the inhibitors
LDN-193189 and SB-431542 have provided useful complemen-
tary tools to interrogate these pathways for the respective activ-
ities of ALK1/2/3/6 and ALK4/5/7. Our data confirmed that
TGF- stimulation resulted in significant phosphorylation of
Smad1/5 in addition to Smad2/3. TGF--induced Smad1/5
phosphorylation was suppressed by SB-431542 or LDN-
193189, although the effect of LDN-193189 was far weaker.
This might suggest that both the BMP-ALKs and ALK5 con-
tributed to this Smad1/5 phosphorylation, either in parallel or
cooperatively. Interestingly, GDF8 also induced some weak
Smad1/5 phosphorylation, although this was hard to quantify
against a background of high Smad1/5 phosphorylation result-
ing fromBMP2 andTGF-. In our experience, 4 or 20 nMGDF8
was able to induce weak phosphorylation of Smad1/5, which
was sensitive to inhibition by dorsomorphin or LDN-193189.
Vice versa, we observed phosphorylation of Smad2/3 in
response to BMP2 stimulation. This was previously reported by
other groups for BMP2 and BMP4 (54, 55). Of note, in our
experiments, this BMP2 activity was inhibited by dorsomor-
phin or LDN-193189 but not by SB-431542, demonstrating that
the kinase activities of ALK4/5/7 were not required.
Thus, our data emphasize that there is significant interaction
between the receptors for TGF- and BMPs with both groups
of Smads. Taking into account recent findings regarding their
effects on various receptors, including type II receptors, dorso-
morphin or LDN-193189 may need to be complemented by
more specific inhibitors to dissect these interactions.
Dorsomorphin and LDN-193189 as Tools to Promote Func-
tional Myogenesis in Vitro—The inhibition of GDF8 signaling
that was observed in immediate pathway readouts was physio-
logically relevant and sufficient to affect the most prominent
function of GDF8 signaling, which is the repression ofmyogen-
esis. At this point, it should be considered that TGF- and BMP
signaling, which are targeted slightly or very potently, respec-
tively, by dorsomorphin and LDN-193189, can be antimyo-
genic in vitro as well. Whereas TGF- appears to counteract
differentiation in myoblasts through a pro-proliferative effect
and through the repression of myogenic transcription factors
(60, 61), the action of BMPs is mediated by up-regulation of Id
(inhibitor of differentiation) proteins, which competitively
inhibit the formation of transcriptionally active dimers of pro-
myogenic transcription factors, such as MyoD and E-box pro-
teins (62). GDF8, in addition to a suggested pro-proliferative
effect (61), represses both the activity and transcription of
MyoD and myogenin (63–65).
The repression of myogenic transcription factors could be
observed immediately in short term GDF8-stimulated C2C12
cells and was significantly counteracted by dorsomorphin and
LDN-193189. Using a luciferase reporter gene assay tomeasure
the activity of the myogenin promoter, we saw that dorsomor-
phin and LDN-193189 were able to enhance myogenin tran-
scription in GDF8-stimulated cells. As expected, both com-
pounds were even more potent against BMP stimulation,
whereas TGF- signaling was only robustly affected by the
ALK4/5/7 inhibitor. Of note, SB-431542 appeared to be a
strong promoter of myogenin expression irrespective of stimu-
lation with ligand.
To prove the potential of dorsomorphin and LDN-193189 to
promote functional myogenesis, cells were treated for longer
periods of time. In contrast to direct and immediate effects of
dorsomorphin and LDN-193189 after short term treatment,
autocrine and serum effects need to be considered in this pro-
tocol. In line with previous publications, inhibition of BMP sig-
naling using noggin, dorsomorphin, or LDN-193189 promoted
myogenesis in C2C12 cells after 3 days of continuous treatment
(49). Of note, the reported effects of dorsomorphin and LDN-
193189 were comparable with those of noggin treatment.
Despite the fact that in our experiments, the effects of dorso-
morphin or LDN-193189 were more pronounced in the pres-
FIGURE 5. Dorsomorphin and LDN-193189 counteract GDF8-induced repression of myogenic differentiation. A, confluent C2C12 cells were switched
from growth medium (GM) to differentiation medium (Diff M; DMEM containing 2% horse serum) with inhibitors (Inh), dorsomorphin or LDN-193189, and
differentiated for 1 day in the presence or absence of ligand (Lig), GDF8. Myogenic transcription factors MyoD andmyogenin were detected by immunoblot-
ting. The concentration of DMSO was 0.05% in all samples. B, C2C12 cells were transfected with a myogenin promoter-dependent firefly luciferase reporter
construct (Myg-luc) 1 day before themediumwas replaced by differentiationmedium (DMEM containing 2% horse serum) supplementedwith the respective
inhibitor. After pretreatment for 30 min, 8 nM GDF8, 5 nM BMP2, or 100 pM TGF-1 was added. DMSO concentration was 0.05% in all samples. Luciferase
activities in lysatesweredetermined after 3 days of differentiation.Bars,mean S.D. (error bars) ofMyg-luciferase activities, normalized tounstimulatedDMSO
controls of four independent experiments. C, confluent C2C12 cells were allowed to differentiate for 3 days in differentiation medium (DMEM containing 2%
horse serum) in the presence or absence of 5M dorsomorphin or 0.5M LDN-193189 and stimulated or not with 8 nM GDF8. DMSO concentrationwas 0.05%
in all samples. At day 3, cells were immunostained for skeletal MHC (green). Nuclei were stained with DAPI (blue). Scale bars, 0.5 mm. Myogenic differentiation
was quantified using digital image analysis of the fractions of nuclei that were in MHC-positive areas and by the relative MHC-positive area in each picture.
Asterisks indicate statistical significance (*, p 0.05; **, p 0.01; ***, p 0.001; ns, p 0.05) (two-way analysis of variance followed by Bonferroni’s multiple
comparison test). D, confluent C2C12 cells were allowed to differentiate for 3 days in the presence or absence of 5M dorsomorphin, 0.5M LDN-193189, 4.4
nM noggin, or combinations of those. Myogenic differentiation was quantified as in C. E, confluent primary humanmyoblasts were switched to differentiation
medium (DMEM containing 2% horse serum) and pretreated for 30 min with 5 M DM, 0.5 M LDN-193189, or DMSO vehicle (0.05%) before stimulation with
8nMGDF8.After 3daysofdifferentiation, cellswere immunostained for skeletalMHC (green). Nucleiwere stainedwithDAPI (blue). Scale bars, 0.5mm.Myogenic
differentiation was quantified as described for C2C12 cells.
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ence of exogenous GDF8 as compared with unstimulated cells,
we conclude that inhibition of autocrine BMP signaling by dor-
somorphin and LDN-193189 at this time point contributed sig-
nificantly to promote myogenic differentiation. Signaling of
endogenous BMPs, however, was reported to decrease rapidly
during the course of differentiation between days 2 and 4,
whereas the expression of TGF- isoforms increases (48, 49).
Expression of endogenous GDF8 was reported to be present in
FIGURE 6. Dorsomorphin treatment facilitates myotube formation. A, confluent C2C12 cells were switched to differentiation medium (DMEM containing
2% horse serum). At day 4 of differentiation, cells were treated with 5 M dorsomorphin (DM), 4.4 nM noggin, both in combination, or with vehicle (0.05%
DMSO). At day 6, cells were immunostained for skeletal MHC (green). Nuclei were stained with DAPI (blue). Scale bars, 0.5 mm. Myogenic differentiation was
quantified as in Fig. 5.B, confluent primary humanmyoblasts onMatrigel-coatedPermanox slideswere switched todifferentiationmedium (DMEMcontaining
2% horse serum). At day 4 of differentiation, cells were treated with 5 M dorsomorphin or vehicle (0.05% DMSO). At day 6, myogenesis was visualized and
quantified as in Fig. 5. C, dorsomorphin-treated C2C12 cells displayed a typical intermittent MHC staining of A-bands and unstained Z-discs. Confluent C2C12
cells were differentiated for 4 days in differentiation medium (DMEM containing 2% horse serum). At days 4 and 5 of differentiation, cells were treated with 5
M dorsomorphin. At day 6, cells were immunostained for skeletal MHC (green). Nuclei were stained with DAPI (blue). Scale bar, 0.5 mm. Right panel, enlarged
area of the MHC displayed in black and white to depict the striated muscle phenotype.
Dorsomorphin and LDN-193189 Inhibit GDF8 Signaling
3400 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 6•FEBRUARY 6, 2015
 at M
ax-D
elbruck-Centrum
 fur on February 18, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
myotubes but not in undifferentiatedC2C12 (66).We thus used
a modified protocol, in which C2C12 cells were allowed to dif-
ferentiate for 4 days before the inhibitors were added in fresh
differentiation medium for an additional 2 days. In this proto-
col, dorsomorphin was still effective to promote myogenic dif-
ferentiation, whereas the effect of noggin had vanished, indicat-
ing that the potential of dorsomorphin to promote late
myogenesis was not related to inhibition of one of the BMP
isoforms that is bound by noggin (i.e. BMP2, -4, or -7). It may,
however, still be possible that inhibition of autocrine signaling
by other BMP isoforms (e.g.BMP6) contributed to the effects of
dorsomorphin also at this stage.
At day 6, extended twitching networks of multinucleated
myotubes were established. In order to evaluate whether the
promyogenic effects of dorsomorphin and LDN-193189
resulted in an increased contractile activity of these networks,
we developed an automated procedure for the quantification of
time lapse movies. This procedure is based on a comparison of
two subsequent frames and has proven very robust against dis-
tortions by moving particles, such as cellular debris. By com-
paring cells that had been treated with dorsomorphin or LDN-
193189 at day 4 for an additional 2 days, we could confirm that
the beneficial effects of these inhibitors result in enhanced
functional myogenesis. We therefore suggest dorsomorphin
and LDN-193189 as tools to generate functional myotubular
networks, whichmay be used as an in vitromodel system. It will
be rewarding in the future to characterize these myotubes in
more detail.
Overall, we have demonstrated a novel and unexpected util-
ity of dorsomorphin and LDN-193189 as inhibitors of GDF8, as
well as of BMP signaling, to promote functional myogenesis in
vitro. However, it is clear that the use of dorsomorphin or LDN-
193189 is not a promising therapeutic option for patients suf-
fering from muscle-wasting diseases, such as Duchenne mus-
cular dystrophy. As reported recently, BMP signaling in vivo is
a strong promoter of muscle hypertrophy, and inhibition of
BMP signaling leads to muscle atrophy (10). Thus, the potent
effect of dorsomorphin and LDN-193189 as repressors of BMP
signaling may provoke adverse effects.
In general, there is increasing evidence that the beneficial
effects of GDF8 inhibition as a therapeutic strategy in muscle-
wasting conditions, such as cachexia, age-related atrophy, or
muscular dystrophies, need to be evaluated with care. It seems
that the hypertrophic phenotype in GDF8-knock-out mice
does not confer increased muscle strength and endurance (67,
68). Recently, it was shown that an increased muscle mass was
not associated with functional improvements because GDF8
knock-out mice suffered from extreme fatigability and exercise
intolerance (69). Of note, similar effects were observed by a
blockade of GDF8 signaling in adult mice using the GDF8 pro-
peptide or a soluble ActRIIB-Fc fusion (69, 70). In the latter
study, developmental consequences of a lack inGDF8 signaling,
which could account for a decreased ratio between oxidative
and glycolytic fibers, were not observed (71). Instead, inhibition
of GDF8 signaling appeared to have direct metabolic effects on
the oxidative capacities of skeletal muscles (70).
Two clinical phase 2 trials using sActRIIB-Fc in Duchenne mus-
cular dystrophy (clinicaltrials.gov identifiers NCT01099761 and
FIGURE 7. Dorsomorphin and LDN-193189 promote the formation of a
contractile myotube network. Confluent C2C12 cells were switched to dif-
ferentiation medium (DMEM containing 2% horse serum). At day 4 of differ-
entiation, cells were treated with 5 M DM, 0.5 M LDN-193189, or vehicle
(0.05%DMSO). At day 6, contractile activitieswere recordedby time lapseDIC
microscopy (3.3 frames/s, 30 s). A, visualization of contractile areas and activ-
ities. Top panels, contracting areas with color coding for the mean activities.
Only active areas are visible, whereas inactive areas appear black. Bottompan-
els, timecourseof activity for the respectivemovies. For each treatment, three
representative data sets are shown: samples with activities at the lower 25%
(left), median (middle), or 75% percentiles (right) of the mean activities of all
samples with the respective treatment. B, median activities in movies of
DMSO (n 28)-, dorsomorphin (n 32)-, and LDN-193189 (n 28)-treated
cells. AU, arbitrary units. Asterisks indicate statistical significance (*, p 0.05;
***, p  0.001) (Kruskal-Wallis test followed by Dunn’s multiple comparison
test).
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NCT01239758) had to be terminated prematurely due to side
effects, despite encouraging improvements in muscle mass. In
this respect, it is noteworthy that sActRIIB is expected to scav-
enge not only GDF8, but also BMP-9, -10, and -11 (16, 72). The
observed side effects, minor bleeding events and reversible vas-
cular abnormalities, are also potentially attributable to the
functions of BMP-9 and -10 in the regulation of angiogenesis
(73). On the other hand, circulating BMP-11, also namedGDF-
11, was recently suggested to be a factor that promotes the
functionality of skeletal muscle (74).
In light of the increasing knowledge about the function of
TGF- superfamily signaling pathways in diverse processes of
development and homeostasis, the development of innovative
strategies for therapeutic intervention seems more challenging
than ever. Our study underscores the importance of extensive
characterization of potential tools, such as small molecule
inhibitors, and it highlights the need to incorporate into this
context the concept of achieving functional specificity in con-
trast to a mere molecular specificity.
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